More Than Just a Back Ache: Addressing the Clinical Challenges of Treating Axial Spondyloarthritis – Activity 2

Release date: November 1, 2018
Expiration date: November 1, 2019

 

FACULTY

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Stanley B. Cohen, MD
Clinical Professor
UT Southwestern Medical Center Dallas
Medical Director
Metroplex Clinical Research Center
Dallas, Texas

M. Elaine Husni, MD, MPH
Assistant Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Vice Chair of Rheumatology
Director, Arthritis and Musculoskeletal Center
Case Western Reserve University
Cleveland, Ohio

ACCREDITED PROVIDER

Chaim Putterman, MD (Peer Reviewer)
Professor, Department of Medicine (Rheumatology)
Professor, Department of Microbiology & Immunology
Albert Einstein College of Medicine
Montefiore Medical Center
Chief, Division of Rheumatology
Bronx, NY

Victor B. Hatcher, PhD (CME Reviewer)
Associate Dean for Continuing Medical Education
Professor, Department of Medicine
Professor, Department of Microbiology
Albert Einstein College of Medicine
Montefiore Medical Center
Bronx, NY

PROGRAM OVERVIEW

Axial spondyloarthritis (axSpA) is an inflammatory degenerative disease. Symptoms at the early disease stages are often confused with chronic back pain, resulting in delayed diagnosis. Failure to diagnose early and initiate effective early treatment can result in disease progression characterized by gradual and increasingly profound deformities of the sacroiliac joints and the axial skeleton. Knowledge and practice gaps among primary care physicians and rheumatologists translate to poor axSpA management and poor patient outcomes. Optimal management of axSpA requires that primary care physicians are able to recognize disease symptoms that raise clinical suspicion to prompt referral to a rheumatologist, who should be knowledgeable and confident to use available therapies to advance treatment. Keeping up to date with data supporting new treatment advances will enable primary care physicians, rheumatologists, and other healthcare practitioners to achieve best outcomes for patients with axSpA through shared decision-making.

TARGET AUDIENCE

This educational initiative has been designed for primary care physicians, internal medicine physicians, rheumatologists, nurse practitioners, and physician assistants. The initiative will also be of interest to other non-specialist healthcare practitioners and specialist physicians who treat patients with axSpA.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Explain the safety and efficacy of new and emerging treatments for ankylosing spondylitis (AS)
  • Formulate a treatment strategy that takes all available therapies into consideration
DIRECTIONS TO THE LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 1, 2018 through November 1, 2019, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pre-test
  • Study the educational activity
  • Complete the post-test and the evaluation form

A certificate will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or higher. Please proceed with the activity until you have successfully passed the post-test, completed the evaluation and received a digital copy of your credit certificate. Your online certificate will be saved on IntegrityCE, which you can access at any time.

MEDIA

Internet

ACCREDITATION STATEMENT

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity or if you have any questions relating to your certificate or other issues with this activity, please contact Integrity Continuing Education at (855) 835-4004 or information@integrityce.com.

CONFLICT OF INTEREST DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, Albert Einstein College of Medicine requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. Albert Einstein College of Medicine resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Calabrese discloses the following:
Consulting Fees: AbbVie, Amgen, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Pfizer, UCB Pharma
Speakers Bureau: AbbVie, Amgen, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Janssen, Pfizer, UCB Pharma

Dr. Cohen discloses the following:
Contracted Research: AbbVie, Amgen, AstraZeneca, Biogen-IDEC, Bristol-Myers Squibb, Genentech, Janssen, Lilly, Merck, Novartis, Pfizer, Roche

Dr. Husni discloses the following:
Consulting Fees: AbbVie, Janssen, Lilly, Novartis, Pfizer, UCB Pharma
Royalties: Co-developer of the Physical Activity Scale for the Elderly (PASE) Questionnaire

Dr. Putterman does not have any real or apparent conflicts of interest to report.

Dr. Hatcher does not have any real or apparent conflicts of interest to report.

The Albert Einstein College of Medicine staff involved in the planning and content review of this activity have no relevant relationships to disclose.

Integrity CE planners and managers have no relevant conflicts of interest to disclose.
Michelle R. Rizzo, ELS (Planner), has no real or apparent conflicts of interest to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Albert Einstein College of Medicine and Integrity Continuing Education do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10
Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Novartis Pharmaceuticals Corporation, UCB, Albert Einstein College of Medicine or Integrity Continuing Education, Inc. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

PROVIDER STATEMENT

Provided by Albert Einstein College of Medicine in collaboration with Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGMENT

Supported by educational grants from Novartis Pharmaceuticals Corporation and UCB.

Continue to Pretest